Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair

Solid Biosciences Inc.

Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.
Ninth patient dosed in IGNITE DMD Phase I/II trial for SGT-001 in Nov 2021 using second-gen manufacturing.
Plans to share additional SGT-001 expression, functional, pulmonary data in H1 2022.
SGT-003 IND-enabling studies in 2022; IND filing targeted early 2023.
Board Chair Ian F. Smith appointed Executive Chair effective Jan 10, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.